Cited 24 times in
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최혜진 | - |
dc.date.accessioned | 2019-12-18T00:58:42Z | - |
dc.date.available | 2019-12-18T00:58:42Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1758-8340 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173304 | - |
dc.description.abstract | Background: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) was effective and well-tolerated in patients with metastatic pancreatic adenocarcinoma (mPAC) that progressed on gemcitabine-based therapy in the global NAPOLI-1 trial. Real-world data may further clarify the outcomes and safety profile of nal-IRI + 5-FU/LV in clinical practice. Methods: This retrospective analysis included patients with mPAC who received nal-IRI + 5-FU/LV following gemcitabine-based therapy under a Managed Access Program in Korea. Results: From January 2017 to April 2018, 86 patients across 10 institutions received nal-IRI + 5-FU/LV (median age, 61 years; 60% male; ECOG performance status, 0-1). A total of 35 (41%) and 51 (59%) patients had received less than two and two or more lines of chemotherapy before inclusion, respectively. At a median follow up of 6.4 months, median overall survival (OS) was 9.4 months (95% confidence interval [CI] 7.4-11.4) and median progression-free survival (PFS) was 3.5 months (95% CI 1.3-5.7). Six-month OS and PFS rates were 65.1% and 37.5%, respectively. Objective response and disease control rates were 10% and 55%, respectively. Most common grade 3-4 toxicities were neutropenia (37.2%), nausea (10.5%), vomiting (9.3%), anorexia (8.1%) and diarrhoea (4.7%). Conclusion: Real-life data for Korean patients indicate that, consistent with NAPOLI-1, nal-IRI + 5-FU/LV is effective and well-tolerated in patients with mPAC that progressed on gemcitabine-based therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Sage | - |
dc.relation.isPartOf | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Changhoon Yoo | - |
dc.contributor.googleauthor | Hyeon-Su Im | - |
dc.contributor.googleauthor | Kyu-pyo Kim | - |
dc.contributor.googleauthor | Do-Youn Oh | - |
dc.contributor.googleauthor | Kyung-Hun Lee | - |
dc.contributor.googleauthor | Hong Jae Chon | - |
dc.contributor.googleauthor | Joo Hoon Kim | - |
dc.contributor.googleauthor | Myoungjoo Kang | - |
dc.contributor.googleauthor | Ilhwan Kim | - |
dc.contributor.googleauthor | Guk Jin Lee | - |
dc.contributor.googleauthor | Sung Yong Oh | - |
dc.contributor.googleauthor | Younak Choi | - |
dc.contributor.googleauthor | Hye Jin Choi | - |
dc.contributor.googleauthor | Seung Tae Kim | - |
dc.contributor.googleauthor | Joon Oh Park | - |
dc.contributor.googleauthor | Baek-Yeol Ryoo | - |
dc.identifier.doi | 10.1177/1758835919871126 | - |
dc.contributor.localId | A04219 | - |
dc.relation.journalcode | J02720 | - |
dc.identifier.eissn | 1758-8359 | - |
dc.identifier.pmid | 31489036 | - |
dc.subject.keyword | chemotherapy | - |
dc.subject.keyword | liposomal irinotecan | - |
dc.subject.keyword | pancreatic adenocarcinoma | - |
dc.subject.keyword | real-world evidence | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | 최혜진 | - |
dc.citation.volume | 11 | - |
dc.citation.startPage | 1758835919871126 | - |
dc.identifier.bibliographicCitation | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, Vol.11 : 1758835919871126, 2019 | - |
dc.identifier.rimsid | 63938 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.